Efficacy and Safety of VX-814 in Alpha 1 PiZZ Genotype

Trial Objective

Efficacy and Safety of VX-814 in Alpha 1 PiZZ GenotypeThe purpose of this study is to learn more about the safety, tolerability and effectiveness of the investigational medication, VX-814, in people with Alpha-1 Antitrypsin Deficiency.

Enrollment

New enrollment for this trial is temporarily paused

Who Can Participate

People who have Alpha-1 Antitrypsin Deficiency may be eligible to participate in this study.

Age: 18-78    Gender: Any Gender


Estimated Time Commitment

42 days

If you are eligible and agree to be in the study, your participation will include a screening period, treatment period and follow-up period. The treatment period will last for 28 days and the follow-up period will last 14 days. In total, you may be asked to visit the study clinic about 8 times.



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kris Eliopoulos

Kris Eliopoulos
303.270.2622

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Vertex Pharmaceuticals Inc.


Request More Information

Due to concerns around COVID-19 and our focus on helping to meet this momentous challenge, we have temporarily paused enrollment for all trials requiring an in-person visit. Please feel free to request additional information about any of the trials we have posted and we will get back to you when enrollment resumes. For more resources and information on COVID-19 please visit our special coronavirus website at www.njhealth.org/coronavirus.


*
*
*
*